About Syndax Pharmaceuticals, Inc.
https://www.syndax.comSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
CEO
Michael A. Metzger
Compensation Summary
(Year 2024)
Salary $715,000
Stock Awards $3,258,450
Option Awards $3,208,211
Incentive Plan Pay $515,515
All Other Compensation $10,000
Total Compensation $7,707,176
Industry Biotechnology
Sector Healthcare
Went public March 2, 2016
Method of going public IPO
Full time employees 270
ETFs Holding This Stock
Summary
Total 114
Showing Top 3 of 114
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 6
Overweight 2
Sector Perform 1
Showing Top 6 of 9
Price Target
Target High $44
Target Low $18
Target Median $36.5
Target Consensus $33.75
Institutional Ownership
BLACKROCK, INC.
Shares:8.63M
Value:$184.93M
KYNAM CAPITAL MANAGEMENT, LP
Shares:8.52M
Value:$182.67M
BLACKROCK INC.
Shares:7.91M
Value:$169.52M
Summary
% Of Shares Owned 84.35%
Total Number Of Holders 262
Showing Top 3 of 262
Market Cap $1.85 B
52w High $22.73
52w Low $8.58
P/E -5.96
Volume 1.53M
Outstanding Shares 86.55M
About Syndax Pharmaceuticals, Inc.
https://www.syndax.comSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $45.87M ▲ | $96.92M ▼ | $-60.72M ▲ | -132.36% ▲ | $-0.7 ▲ | $-57.7M ▲ |
| Q2-2025 | $37.96M ▲ | $106.03M ▲ | $-71.85M ▲ | -189.28% ▲ | $-0.83 ▲ | $-63.99M ▲ |
| Q1-2025 | $20.04M ▲ | $102.91M ▼ | $-84.85M ▲ | -423.34% ▲ | $-0.99 ▲ | $-83.76M ▲ |
| Q4-2024 | $7.68M ▼ | $104.05M ▲ | $-94.17M ▼ | -1.23K% ▼ | $-1.1 ▼ | $-89.36M ▼ |
| Q3-2024 | $12.5M | $102.08M | $-84.13M | -673.01% | $-0.98 | $-84.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $454.17M ▼ | $551.79M ▼ | $436.36M ▼ | $115.43M ▼ |
| Q2-2025 | $468.71M ▼ | $596.15M ▼ | $438.73M ▲ | $157.42M ▼ |
| Q1-2025 | $516.31M ▼ | $640.71M ▼ | $425.65M ▼ | $215.06M ▼ |
| Q4-2024 | $582.91M ▲ | $724.82M ▲ | $436.69M ▲ | $288.12M ▼ |
| Q3-2024 | $389.61M | $425.81M | $59.38M | $366.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-60.72M ▲ | $-70.53M ▲ | $72.43M ▲ | $6.28M ▲ | $8.17M ▲ | $-70.67M ▲ |
| Q2-2025 | $-71.85M ▲ | $-87.8M ▲ | $41.89M ▼ | $551K ▼ | $-45.36M ▼ | $-87.8M ▲ |
| Q1-2025 | $-84.85M ▲ | $-95.16M ▼ | $94.14M ▲ | $930K ▼ | $-90K ▼ | $-95.16M ▼ |
| Q4-2024 | $-94.17M ▼ | $-57.39M ▲ | $-268.97M ▼ | $347.43M ▲ | $21.06M ▼ | $-57.39M ▲ |
| Q3-2024 | $-84.13M | $-62.32M | $86.85M | $3.1M | $27.62M | $-62.32M |
Revenue by Products
| Product | Q2-2025 | Q3-2025 |
|---|---|---|
 Collaboration revenue | $10.00M ▲ | $10.00M ▲ |
 Product | $30.00M ▲ | $30.00M ▲ |
CEO
Michael A. Metzger
Compensation Summary
(Year 2024)
Salary $715,000
Stock Awards $3,258,450
Option Awards $3,208,211
Incentive Plan Pay $515,515
All Other Compensation $10,000
Total Compensation $7,707,176
Industry Biotechnology
Sector Healthcare
Went public March 2, 2016
Method of going public IPO
Full time employees 270
ETFs Holding This Stock
Summary
Total 114
Showing Top 3 of 114
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Buy 6
Overweight 2
Sector Perform 1
Showing Top 6 of 9
Price Target
Target High $44
Target Low $18
Target Median $36.5
Target Consensus $33.75
Institutional Ownership
BLACKROCK, INC.
Shares:8.63M
Value:$184.93M
KYNAM CAPITAL MANAGEMENT, LP
Shares:8.52M
Value:$182.67M
BLACKROCK INC.
Shares:7.91M
Value:$169.52M
Summary
% Of Shares Owned 84.35%
Total Number Of Holders 262
Showing Top 3 of 262